Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Enterobacteriaceae fimbrial adhesins are a family of surface proteins expressed by Gram-negative bacteria, notably Escherichia coli, Klebsiella pneumoniae, and Salmonella spp., that mediate adhesive attachment to host cells[1][2][3][4]. The canonical member is the FimH adhesin, which resides at the tip of type 1 fimbriae (pili). FimH recognizes and binds to terminal mannose residues on host glycoproteins, enabling bacterial colonization, especially in the urinary tract[1][2]. The adhesin operates through a shear-dependent, allosteric catch-bond mechanism in which binding affinity increases under mechanical force, helping bacteria resist wash-off in the urinary tract[1][4]. Type 1 fimbriae are essential for initial stages of infection, including adherence to uroepithelial cells, thus playing a central role in urinary tract infections[1][2]. Diversity among FimH variants and fimbrial shaft compositions modulates tissue specificity and binding strength, which has implications for bacterial pathogenesis and host specificity[1][2][6]. Note: - "Enterobacteriaceae fimbrial adhesins" is a plural/generic term referring to a class of adhesins, not a single molecular target. The most studied and therapeutically relevant is "FimH adhesin," and structured information should refer to this canonical form when possible[1][4][6]. - No standard abbreviation for the plural term; "FimH" is widely used for the gene/protein. - Not a classic drug target in existing therapeutics, but an active field of anti-adhesion drug and vaccine research targeting FimH or analogous adhesins[1]. Summary of structure/function: - FimH consists of a mannose-binding lectin (N-terminal) domain and a pilin (C-terminal) domain[1][4]. - Mutations (such as S62A) can increase affinity and alter shear dependency, impacting pathogenic potential[1]. - Different fimbriae exist within Enterobacteriaceae, each with distinct but sometimes overlapping receptor specificity[2][3][6]. Reason for is_incorrect:true: - "Enterobacteriaceae fimbrial adhesins" is not a singular standardized target name but rather a family/class; scientific and therapeutic discussions focus on the specific adhesin (usually FimH adhesin)[1][4]. - For structured datasets, use the specific singular canonical name "FimH adhesin" or analogous protein from the bacterial species of interest.
Inhibition of fimbrial adhesion; competitive inhibition of the mannose-binding site; prevention of bacterial attachment to host cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Enterobacteriaceae fimbrial adhesin.